addenda and errata
1-[2-(5-Nitro-1H-benzimidazol-1-yl)ethyl]morpholinium chloride. Corrigendum
aDepartment of Physics, Faculty of Arts and Sciences, Erciyes University, 38039 Kayseri, Turkey, bDepartment of Chemistry, Faculty of Arts and Sciences, Ínönü University, 44280 Malatya, Turkey, and cDepartment of Physics, Faculty of Arts and Sciences, Ondokuz Mayıs University, 55139 Samsun, Turkey
*Correspondence e-mail: akkurt@erciyes.edu.tr
In the paper by Akkurt, Türktekin, Küçükbay, Yılmaz & Büyükgüngör [Acta Cryst. (2005), E61, o166–o168], the experimental section is incorrect. The correct experimental section is given below.
1. Experimental
The title compound was synthesized by nucleophilic substitution of 5-nitrobenzimidazole with N-(2-chloroethyl)morpholine hydrochloride. A mixture of 5-nitrobenzimidazole (2.00 g, 12.27 mmol) and N-(2-chloroethyl)morpholine hydrochloride (2.28 g, 12.27 mmol) in DMF (8 ml) was heated on a water bath for 3 h. All volatiles were then removed in vacuo. The crude product obtained was crystallized from an EtOH/Et2O (3:1) mixture (yield: 2.76 g, 72%; m.p. 556–557 K). 1H NMR (D2O): δ 3.67 (t, CH2CH2-morpholine, 2H), 3.63 (t, ring methylene, 4H), 3.86 (t, CH2CH2-morpholine, 2H), 4.71 (t, ring methylene, 4H), 7.56–8.36 (m, Ar-H, 4H). 13C NMR (D2O): δ 39.34, 52.09, 54.70, 63,62, 107.53, 118.73, 119.41, 143.68. Analysis calculated for C13H17ClN4O3: C 49.92, H 5.44, N 17.92%; found: C 49.87, H 5.44, N 17.76%.